A Phase Ib Study of HMPL-523 in Immune Thrombocytopenia Patients

2019-05-20 19:54:21 | BioPortfolio


This is a radomized, double blinded, placebo-controlled phase Ib clinical trial in adult patients with immune thrombocytopenia. The trial has two parts: dose escalation (stage 1) and dose expansion (stage 2). No cross-over treatment will be allowed during the study.


Approximate 51 to 60 patients will be enrolled in dose ascelation (3 cohorts, 8 subjects each with the ratio of 3:1 vs Placebo) and dose expansion (1 cohort, 27-36 subjects with the ratio of 2:1 vs Placebo).

Study Design


Immune Thrombocytopenia


HMPL-523, Placebo


Blood diseases hospital, Chinese academy of medical university


Not yet recruiting


Hutchison Medipharma Limited

Results (where available)

View Results


Published on BioPortfolio: 2019-05-20T19:54:21-0400

Clinical Trials [763 Associated Clinical Trials listed on BioPortfolio]

A Study of HMPL-689 in Healthy Volunteers

The purpose of this study is to evaluate the safety and tolerability of a single dose of HMPL-689 in healthy volunteers To determine the pharmacokinetic profile of single oral doses of HMP...

Phase II Study of HMPL-004 in Patients With Ulcerative Colitis

The purpose of this study is to evaluate the safety and efficacy of HMPL-004 in patients with active mild to moderate ulcerative colitis (UC), compared with placebo.

A Study to Investigate the Efficacy and Safety of S-888711 Tablets Administered to Adult Subjects With Immune Thrombocytopenia (ITP)

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, parallel-group study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of...

Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)

Study in patients with persistent and chronic Immune Thrombocytopenia (ITP), who have failed to respond or relapsed after prior therapy, with a platelet count

A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523

The primary objective of this study is to assess the safety and tolerability of a single dose of 5, 20, 50, 100, 200 and 300 mg HMPL-523 in Part A, followed by multiple doses of selected s...

PubMed Articles [6028 Associated PubMed Articles listed on BioPortfolio]

Involvement of Interferon-γ + 874A/T Polymorphism in the Pathogenesis of and Therapeutic Response to Immune Thrombocytopenia.

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by symptoms of thrombocytopenia and bleeding due to production of autoantibodies against platelets. Recently, the occurrence of pol...

Macrothrombocytopenia associated with a rare GFI1B missense variant confounding the presentation of immune thrombocytopenia.

Growth factor-independent 1B (GFI1B) variants are a rare cause of thrombocytopenia. We report on a male child who was initially diagnosed with immune thrombocytopenia. However, subtle clinical signs l...

Acute thrombocytopenia: picking a way through a paucity of platelets.

Thrombocytopenia is defined as a platelet count under 150x10/litre. It may be found as a bystander to other pathology or directly related to an underlying haematological condition. Apart from laborato...

Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia.

Among patients with chronic immune thrombocytopenia (cITP), little is known regarding risk factors for cardiovascular and bleeding outcomes and how these events influence mortality.

Combined subtotal gastrectomy and splenectomy after partial splenic embolization for a patient with gastric cancer and immune thrombocytopenic purpura: A case report.

Immune thrombocytopenic purpura is an acquired thrombocytopenia. Preoperative management of thrombocytopenia is important in patients with gastric cancer. Partial splenic embolization can be effective...

Medical and Biotech [MESH] Definitions

An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6)

Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

Regeneration of normal immune function after immune depleting procedures or infections (e.g., HEMATOPOIETIC STEM CELL TRANSPLANTATION). Delayed and incomplete reconstitution of the ADAPTIVE IMMUNE system in particular involving T-CELLS is associated with increase or relapse of infection.

An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.

More From BioPortfolio on "A Phase Ib Study of HMPL-523 in Immune Thrombocytopenia Patients"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Searches Linking to this Trial